Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

This is a multicenter, single arm, open-label, Phase 2 study in high risk smoldering myeloma patients. The primary objective is to determine the efficacy of Elranatamab in patients with previously untreated high-risk SMM. The key-secondary objective is to determine the safety of Elranatamab in patients with previously untreated high-risk SMM.

Trial Details

NCT ID
NCT06183489
Phase
PHASE2
Sponsor
Stichting European Myeloma Network
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Elranatamab
Locations (sample)
  • Helsinki, Finland|60.16952,24.93545
  • La Roche-sur-Yon, France|46.66974,-1.42757
  • Lille, France|50.63391,3.05512
  • Montpellier, France|43.61093,3.87635
  • Nantes, France|47.21725,-1.55336

Key Eligibility Criteria

  • \>18 years of age
  • Diagnosis of SMM for ≤5 years with measurable disease, defined as serum M protein:
  • ≥1g/dL or urine M protein ≥200 mg/24 hours or involved serum FLC ≥100 mg/Land abnormal serum FLC ratio.
  • BMPCs ≥10% and \<60%

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →